Reflecting these advantages, the 2023 treatment algorithm for type 2 diabetes, published by the Japanese Diabetes Society, recommends GLP-1 RAs for patients with cardiovascular disease or chronic kidney disease, anticipating additional benefits [35, 36]
Do not use this if pregnant
There's a whole pipeline of more GLP-1 drugs coming, and anti-obesity drugs that target other things completely
The second one is the CARMELINA trial, initiated in 2013 and aimed to investigate the long term impact on cardiovascular morbidity, mortality and renal function in a selected population of 8300 patients with T2DM and renal compromise, comparing outcomes against placebo, on a background of standard of care [95]
Acetyl L-Carnitine is a specific form of carnitine that has the ability to cross the blood-brain barrier
Discuss this with your provider before switching